(Q35741527)

10 August 2017

1 reference

title

Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer (English)

1 reference

10 August 2017

1 reference

Lynsey A McHugh

1

1 reference

10 August 2017

T R Leyshon Griffiths

2

1 reference

10 August 2017

Marina Kriajevska

3

1 reference

10 August 2017

R Paul Symonds

4

1 reference

10 August 2017

J Kilian Mellon

5

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

63

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

619-624

1 reference

Estimates of cancer incidence and mortality in Europe in 1995

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Overview of gemcitabine triplets in metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

The epidermal growth factor receptor and the prognosis of bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

The pathway to signal achievement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.060

10.1016/J.UROLOGY.2003.10.060

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference